The present invention relates to viruses that are engineered to contain a surface ligand molecule which targets the virus to a cell of interest. In particular non-limiting embodiments, the cell of interest is desirably ablated and may be a cancer cell, an infected cell, a cell exhibiting a non-malignant proliferative disorder, or a cell of the immune system. Alternatively, the cell of interest is a target for gene therapy.